Considering the latest class of revolutionary drugs fighting against HIV infection and AIDS, this comprehensive reference thoroughly examines the development and properties of HIV protease inhibitors from clinical and scientific perspectives, discussing how protease inhibitors changed the FDA approval process-enhancing the collaboration between regulatory authorities and drug developers.
Spotlights protease inhibitors as the cornerstone drugs of the first HAART regimens-key components of long-term viral suppression and immune restoration, and in secondary and tertiary regimens!
Evaluating protease inhibitors as therapeutic options and research tools, Protease Inhibitors in AIDS Therapy
reviews the impact of advances in recombinant DNA technology for understanding and treating HIV and AIDS
highlights a variety of strategies and techniques for drug discovery and development illustrated by success stories of pharmaceutical companies and biotechnology start-up firms
summarizes the pharmacokinetics, metabolism, and drug interactions of protease inhibitors
details preliminary clinical studies on oral bioavailability, pharmacokinetic profiling, efficacy, resistance, and tolerability
describes available efficacy data for marketed inhibitors and those in clinical development
reports on efforts to manage antiviral resistance in the clinic and improve patient adherence to complex drug therapy
Containing more than 600 helpful literature references, drawings, photographs, and tables, Protease Inhibitors in AIDS Therapy serves for an essential reference for infectious disease specialists, epidemiologists, virologists, immunologists, pharmacologists, medicinal chemists and biochemists, microbiologists, hematologists, hepatologists, and medical students in these disciplines.
Publisher: Taylor & Francis Inc
Number of pages: 328
Weight: 590 g
Dimensions: 279 x 216 x 21 mm
You may also be interested in...
Would you like to proceed to the App store to download the Waterstones App?